Skip to content
Screener

Protagonist Therapeutics PTGX EV / EBITDA

EV / EBITDA at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
10.1×-0.2×
Eli Lilly logo
Eli LillyLLY
31.3×-7.9×
Amgen logo
AmgenAMGN
15.7×+0.7×
Incyte logo
IncyteINCY
10×+1.0×
AbbVie logo
AbbVieABBV
19.8×—

Other financials

Income statement

See full
Revenue$213.5M+3,749%
Operating income$158.8M+478%
Net income$162.8M+568%
EPS (diluted)$2.29+516%

Balance sheet

See full
Cash & equivalents$420.1M+149%
Total debt$9.2M-18.3%
Total equity$841.5M+26.0%
Total assets$885.5M+23.3%

Cash flow

See full
Operating cash flow$219.1M—
CapEx$168.0K-79.3%
Free cash flow$218.9M—

Valuation

See full
Market cap$8.83B+165%
Enterprise value$8.42B+165%
P/E106.5×+42.4×
P/S31.3×+15.4×

Profitability

See full
Operating margin20.7%+9.2pp
Net margin29.4%+4.5pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity11%+2.4pp
Debt / equity0×0.0×
Current ratio21.7×+4.7×

Where this comes from

Calculated from Protagonist Therapeutics’s reported figures.

enterprise value/ebitda=124.8×

Based on the most recent quarter.

The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091123

FAQ

What is Protagonist Therapeutics's EV / EBITDA?
Protagonist Therapeutics (PTGX) reported EV / EBITDA of 124.8× in Q2 2026.
How has Protagonist Therapeutics's EV / EBITDA changed year-over-year?
Protagonist Therapeutics's EV / EBITDA decreased by 2.1% year-over-year, from 127.5× to 124.8×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Protagonist Therapeutics's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude